Johnson & Johnson $JNJ Shares Sold by Nan Shan Life Insurance Co. Ltd.

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Nan Shan Life Insurance Co. Ltd. decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 14.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 261,045 shares of the company's stock after selling 43,229 shares during the quarter. Johnson & Johnson makes up about 1.0% of Nan Shan Life Insurance Co. Ltd.'s holdings, making the stock its 28th largest position. Nan Shan Life Insurance Co. Ltd.'s holdings in Johnson & Johnson were worth $43,292,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Legacy Financial Advisors Inc. grew its holdings in shares of Johnson & Johnson by 14.7% during the first quarter. Legacy Financial Advisors Inc. now owns 18,294 shares of the company's stock worth $3,034,000 after buying an additional 2,350 shares during the last quarter. Andina Capital Management LLC purchased a new stake in Johnson & Johnson in the 1st quarter valued at approximately $330,000. Texas Capital Bank Wealth Management Services Inc boosted its holdings in Johnson & Johnson by 39.0% in the 1st quarter. Texas Capital Bank Wealth Management Services Inc now owns 8,730 shares of the company's stock valued at $1,448,000 after purchasing an additional 2,448 shares in the last quarter. Colonial Trust Advisors boosted its holdings in Johnson & Johnson by 3.8% in the 1st quarter. Colonial Trust Advisors now owns 129,264 shares of the company's stock valued at $21,437,000 after purchasing an additional 4,735 shares in the last quarter. Finally, Financial Advisors Network Inc. raised its position in shares of Johnson & Johnson by 52.1% during the 1st quarter. Financial Advisors Network Inc. now owns 5,205 shares of the company's stock worth $863,000 after purchasing an additional 1,782 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on the stock. Barclays lifted their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Bank of America boosted their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research note on Thursday, July 17th. Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Royal Bank Of Canada boosted their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Finally, Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Stock Up 0.4%

Shares of Johnson & Johnson stock traded up $0.7890 during trading on Wednesday, reaching $178.5890. The company had a trading volume of 9,028,878 shares, compared to its average volume of 8,462,277. The company has a market cap of $430.10 billion, a price-to-earnings ratio of 19.10, a price-to-earnings-growth ratio of 2.26 and a beta of 0.41. The firm's fifty day moving average is $162.13 and its 200-day moving average is $158.73. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $180.61.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.